Lv1
48 积分 2024-12-02 加入
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
4天前
已完结
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
19天前
已完结
Recent advances in natural polysaccharides against hepatocellular carcinoma: A review
26天前
已完结
The combination of circulating IgM and geriatric nutritional risk index predicts the prognostic of hepatocellular carcinoma patients who underwent immune checkpoint inhibitors
29天前
已完结
Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2–Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Receptor 2–Expressing or Mutated Advanced Solid Tumors: A Global Phase I Trial
1个月前
已完结
Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients
2个月前
已完结
3550 POSTER Capecitabine plus hepatic intra-arterial epirubicin and cisplatin in unresectable biliary cancer: a phase II study
2个月前
已完结
Arterial infusion of cisplatin plus S-1 against unresectable intrahepatic cholangiocarcinoma
2个月前
已关闭
Hepatic arterial infusion of GEMOX plus systemic gemcitabine chemotherapy combined with lenvatinib and PD-1 inhibitor in large unresectable intrahepatic cholangiocarcinoma
2个月前
已完结
First-line hepatic arterial infusion chemotherapy plus lenvatinib and PD-(L)1 inhibitors versus systemic chemotherapy alone or with PD-(L)1 inhibitors in unresectable intrahepatic cholangiocarcinoma
2个月前
已完结
皖公网安备34019202002308
